Spotify Apple Youtube

Category: Companies

All Podcast Categories
S4-34.2 - Practical and Plausible Notes On Injectables Versus Oral Agents

S4-34.2 – Practical and Plausible Notes On Injectables Versus Oral Agents

Stephen Harrison, Mazen Noureddin, Jörn Schattenberg, Louise Campbell and Roger Green unpack compelling drug development stories from this month’s EASL Congress and ADA meetings. This conversation digs deeper into the FASCINATE-2 interim analysis data at week 26 of the 52-week trial. The discussion develops into practical and plausible considerations in a comparison between injectable and oral agents.

July 29, 2023
S4-34 - Drug Development Stories from EASL and ADA: Part 2

S4-34 – Drug Development Stories from EASL and ADA: Part 2

Stephen Harrison, Mazen Noureddin, Jörn Schattenberg, Louise Campbell and Roger Green unpack compelling drug development stories from this month’s EASL Congress and ADA meetings. The session explores a range of topics around the subject of drug development, including notes on orals versus injectables, diabetes medications with potential in the NASH space, new clinical trial data, different drug classes and much more.

July 26, 2023
S4-33.5 - From the Vault: ILC 2022 Looking Back: NASH Is a Complex Disease

S4-33.5 – From the Vault: ILC 2022 Looking Back: NASH Is a Complex Disease

Last year, roughly 5,000 liver community stakeholders gathered in London for the 2022 International Liver Congress (#ILC2022,) the first major hepatology Congress to be held in person since the start of the pandemic (smaller, but very valuable meetings like NASH-TAG, LiverCONNECT and Paris NASH have taken place with an in-person component, but the International Liver Congress and The Liver Meeting have not). This conversation From the Vault revisits still relevant takeaways as the podcast continues its coverage of emerging stories from EASL Congress 2023.

July 23, 2023
S4-33.1 - EASL Congress 2023: Focus on New Nomenclature

S4-33.1 – EASL Congress 2023: Focus on New Nomenclature

Sven Francque and Ian Rowe join Jörn Schattenberg and Roger Green to discuss the new NAFLD/NASH nomenclature shared at EASL Congress 2023. The groups outlines what the changes entail and shares practical considerations around how to implement the changes in different settings and with patients.

July 22, 2023
S4-32.4 - The Potential of NASH Drugs as Adjuvant Therapy

S4-32.4 – The Potential of NASH Drugs as Adjuvant Therapy

Stephen Harrison and Jörn Schattenberg join Roger Green to digest and discuss key takeaways from the recently concluded EASL Congress 2023 and ADA 83rd Scientific Sessions. This final conversation considers important topics yet to be addressed in the preceding sessions. One of the prevailing themes explored is the potential of NASH drugs as adjuvant therapy.

July 16, 2023
S4-32.3 - Discussing Other Drugs in the Therapeutic Landscape

S4-32.3 – Discussing Other Drugs in the Therapeutic Landscape

Stephen Harrison and Jörn Schattenberg join Roger Green to digest and discuss key takeaways from the recently concluded EASL Congress 2023 and ADA 83rd Scientific Sessions. In this conversation, the group moves on from analysis around resmetirom to discuss other drug classes in the therapeutic landscape.

July 15, 2023
S4-32.2 - Why We Should Develop Deeper Understanding of Liver Volume

S4-32.2 – Why We Should Develop Deeper Understanding of Liver Volume

Stephen Harrison and Jörn Schattenberg join Roger Green to digest and discuss key takeaways from the recently concluded EASL Congress 2023 and ADA 83rd Scientific Sessions. In this conversation, the group continues to unpack fresh data on resmetirom, discuss its safety profile and speculate ideas around how the field could benefit from an improved understanding of liver volume dynamics.

July 15, 2023
Stay In Touch
Apple Spotify Youtube

Sponsoring Partnerships

Sponsoring partnerships with SurfingMASH present a multifaceted avenue for companies seeking to amplify their brand presence and engage with targeted audiences.

Learn More